Abstract Number: 547 • 2017 ACR/ARHP Annual Meeting
Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: In the United Kingdom (UK), rituximab (RTX) or a second tumour necrosis factor inhibitor (TNFi) are both permitted treatment options for patients with rheumatoid…Abstract Number: 548 • 2017 ACR/ARHP Annual Meeting
LDL and HDL Changes with Sirukumab Treatment Are Anti-Atherogenic: Results from Two Phase 3 Trials in Patients with Rheumatoid Arthritis
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in RA in the phase…Abstract Number: 549 • 2017 ACR/ARHP Annual Meeting
Increases in Lipid Levels Following Sirukumab Treatment Are Associated with Suppression of Inflammation in Rheumatoid Arthritis: Results from Two Phase 3 Trials
Background/Purpose: Understanding interactions of inflammatory cytokines and lipid metabolism in RA is of considerable interest. Blocking IL-6 receptor elevates lipid levels in RA while lowering…Abstract Number: 550 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Tocilizumab from Large Clinical Trial and Postmarketing Populations
Background/Purpose: Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody targeted against the interleukin-6 receptor that was approved to treat rheumatoid arthritis (RA) in the EU…Abstract Number: 551 • 2017 ACR/ARHP Annual Meeting
Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-
Background/Purpose: More than 4 years have passed since 7 biologics became available for patients with rheumatoid arthritis (RA) in Japan, still lack reliable evidence in…Abstract Number: 552 • 2017 ACR/ARHP Annual Meeting
Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis and…Abstract Number: 553 • 2017 ACR/ARHP Annual Meeting
Decreased Circulating CXCR3+CCR9+ Th Cells Coincides with Elevated Levels of Their Ligands CXCL10 and CCL25 in the Salivary Gland of Sjögren’s Syndrome Patients Which Synergistically Facilitate Th Cell Migration
Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by dryness and lymphocytic infiltration in the salivary glands. CXCR3+ T cells and ligands CXCL9/10/11 are known to…Abstract Number: 554 • 2017 ACR/ARHP Annual Meeting
Prognostic Significance of Double Positive Anti Ro/SS-a and La/SS-B Antibodies in Patients with Primary Sjogren’s Syndrome: Prospective Salivary Gland Ultrasound Study
Background/Purpose: The aim of the study was to assess the diagnostic value of salivary gland ultrasonography (SGUS) as a single test for the detection of…Abstract Number: 555 • 2017 ACR/ARHP Annual Meeting
The Corrected QT(QTc) Interval Is Associated with Myocardial Fibrosis in Primary Sjögren Syndrome, Assessed By a Cardiac Magnetic Resonance Approach: A Prospective Pilot Study at a Single Center
Background/Purpose: Congenital heart block in the fetus and neonate, which can cause acquired QT prolongation, may be associated with maternal anti-SS-A/anti-SS-B autoantibodies. However, there are…Abstract Number: 556 • 2017 ACR/ARHP Annual Meeting
Identification and Validation of S100 Salivary Proteins As Putative Biomarkers for Different Subsets of Primary Sjögren’s Syndrome Patients
Background/Purpose: S100 A proteins are multifunctional proteins expressed predominantly by myeloid cells, with a regulatory role in a variety of cellular processes including inflammation. Recently,…Abstract Number: 557 • 2017 ACR/ARHP Annual Meeting
Enhanced Expression of NLRP3 Inflammasome-Related Inflammation in Peripheral Blood Mononuclear Cells in Sjögren’s Syndrome
Background/Purpose: Sjögren's syndrome is a systemic autoimmune disease characterized by lymphocyte infiltration and subsequent dysfunction of exocrine glands, finally leading to dryness in the exocrine…Abstract Number: 558 • 2017 ACR/ARHP Annual Meeting
Salivary Syndecan-1 Levels Are Associated with Salivary Gland Dysfunction and Immune Dysregulation in Patients with Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SJS) is a chronic autoimmune disorder with lymphocytic infiltration of exocrine and non-exocrine epithelia, in which epithelial cells play a critical role…Abstract Number: 559 • 2017 ACR/ARHP Annual Meeting
Performance of Multiple Platforms for Autoantibody Testing in Sjogren’s Syndrome
Background/Purpose: The research classification and clinical diagnosis of SjšgrenÕs syndrome (SS) relies heavily on the detection of autoantibodies against Ro/SSA and La/SSB, particularly in the…Abstract Number: 560 • 2017 ACR/ARHP Annual Meeting
Clinical Relevance of Serum Free Light Chain Level As Biomarker in Primary Sjögren′s Syndrome
Background/Purpose: During immunoglobulin synthesis in B-cells, kappa and lambda light chains are produced in excess compared to heavy chains, and the surplus of light chains…Abstract Number: 561 • 2017 ACR/ARHP Annual Meeting
Comprehensive Immuno-Phenotyping of Follicular Helper T Cell and B Cell Subpopulations in Primary Sjögren’s Syndrome
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by immune cell infiltration in the salivary glands resulting in ocular and oral dryness.…
ACR Meeting Abstracts